Adoptive chimeric antigen receptor cell therapy for the treatment of patients with Acute myeloid leukemia: development of preclinical models to assess efficacy and safety
Roma
Tempo indeterminato
Full time
13 giorni fa
Offer DescriptionThe prognosis of Acute myeloid leukemia (AML) is still unsatisfactory. Immunotherapy based on the use of T cells genetically modified through chimeric antigen receptors (CAR) for redirecting their specificity towards tumor cells has shown unprecedented results in B-cell malignancies. So far, translation of CAR T cell therapy in AML is hindered by several obstacles. Preliminary evidence of the use of CD123-directed CAR-T cells for treatment of patients with AML showed promising anti-leukemic activity without myelosuppressive effects. Allogeneic immune effector cells other than T lymphocytes constitute an attractive alternative for implementing ready-to-use CAR cell therapeutic approaches in AML. In this research project, we will investigate innovative approaches based on the generation of allogeneic natural killer and cytokine-induced killer cells to kill AML blasts.RequirementsAdditional InformationEligibility criteriaEligible destination country/ies for fellows:
Italy
Eligibility of fellows: country/ies of residence:
EUROPE
Eligibility of fellows: nationality/ies:
EUROPE
Website for additional job detailsWork Location(s)Number of offers available 1 Company/Institute UNIVERSITA' CATTOLICA DEL SACRO CUORE Country Italy GeofieldWhere to apply WebsiteContact CityROMA WebsiteSTATUS: EXPIRED